Find Faculty
Kevin Costa, PhD
img_Kevin Costa
ASSOCIATE PROFESSOR | Medicine, Cardiology
212-241-7122
email
Research Topics
Biomechanics/Bioengineering, Cardiovascular, Cellular Differentiation, Computer Simulation, Cytoskeleton, Mathematical Modeling of Biomedical Systems, Muscle Cells, Regeneration, Stem Cells, Tissue Engineering, Wound Healing
Multi-Disciplinary Training Area
Artificial Intelligence and Emerging Technologies in Medicine [AIET], Development Regeneration and Stem Cells [DRS], Disease Mechanisms and Therapeutics (DMT)
Atomic Force Microscopy And Cell Mechanobiology
This research is focused on enhancing and expanding the kinds of measurements that can be obtained from AFM mechanical testing experiments, to better understand how physical forces impact cardiovascular cell function.
Tissue Engineering And Cardiac Repair
This research involves development of innovative new tools and approaches combining soft lithography, cell patterning, and bioreactor design for tissue and organoid engineering, with the overall objective of improving the understanding and efficacy of novel cell- and gene-therapy based approaches for cardiac repair.

MS, Boston University

PhD, University of California, San Diego

140
Publications

Selected Publications

Integrative gene regulatory network analysis discloses key driver genes of fibromuscular dysplasia. Valentina d’Escamard, Daniella Kadian-Dodov, Lijiang Ma, Sizhao Lu, Annette King, Yang Xu, Shouneng Peng, Bhargravi V′Gangula, Yu Zhou, Allison Thomas, Katherine C. Michelis, Emir Bander, Rihab Bouchareb, Adrien Georges, Aya Nomura-Kitabayashi, Robert J. Wiener, Kevin D. Costa, Elena Chepurko, Vadim Chepurko, Marika Fava, Temo Barwari, Anelechi Anyanwu, Farzan Filsoufi, Sander Florman, Nabila Bouatia-Naji, Lukas E. Schmidt, Manuel Mayr, Michael G. Katz, Ke Hao, Mary C.M. Weiser-Evans, Johan L.M. Björkegren, Jeffrey W. Olin, Jason C. Kovacic. Nature Cardiovascular Research

Generation and characterization of novel human induced pluripotent stem cell (iPSC) lines originating from five asymptomatic individuals carrying the PLN-R14del pathogenic variant and a non-carrier relative. Valentina Balducci, Francesco Scardigli, Magdalena Harakalova, J. Peter. van Tintelen, Pieter A. Doevendans, Kevin D. Costa, Irene C. Turnbull, Joost P. G. Sluijter, Francesca Stillitano. Stem Cell Research

Designing a Bioreactor to Improve Data Acquisition and Model the Throughput of Engineered Cardiac Tissues. Camille C. van Neste, Karlo A. Wiley, Serena W. Chang, Joseph Borrello, Irene C. Turnbull, Kevin D. Costa. Journal of Visualized Experiments

View All Publications

Creating Heart Stem Cells

Atran Berg Laboratory Building Floor 3 Room 39

1428 Madison Ave

New York, NY 10029

212-241-7122

Hess CSM Building Floor 7 Room 105

1470 Madison Ave

New York, NY 10029

Hess CSM Building Floor 7 Room 201

1470 Madison Ave

New York, NY 10029

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Costa during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Board Service

  • Novoheart US Corp

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Medera Biopharmaceutical

Founder/Co-Founder/Partner

  • Novoheart International Ltd

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.